Terms: = Skin cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Prognosis
8 results:
1. Tumor-independent Detection of Inherited Mismatch Repair Deficiency for the Diagnosis of Lynch Syndrome with High Specificity and Sensitivity.
Kansikas M; Vähätalo L; Kantelinen J; Kasela M; Putula J; Døhlen A; Paloviita P; Kärkkäinen E; Lahti N; Arnez P; Kilpinen S; Alcala-Repo B; Pylvänäinen K; Pöyhönen M; Peltomäki P; Järvinen HJ; Seppälä TT; Renkonen-Sinisalo L; Lepistö A; Mecklin JP; Nyström M
Cancer Res Commun; 2023 Mar; 3(3):361-370. PubMed ID: 36875157
[TBL] [Abstract] [Full Text] [Related]
2. Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Dogan A; Kern P; Schultheis B; Häusler G; Rezniczek GA; Tempfer CB
BMC Cancer; 2018 Apr; 18(1):463. PubMed ID: 29690864
[TBL] [Abstract] [Full Text] [Related]
3. Microsatellite Instability as a Biomarker for PD-1 Blockade.
Dudley JC; Lin MT; Le DT; Eshleman JR
Clin Cancer Res; 2016 Feb; 22(4):813-20. PubMed ID: 26880610
[TBL] [Abstract] [Full Text] [Related]
4. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome.
Ripperger T; Schlegelberger B
Eur J Med Genet; 2016 Mar; 59(3):133-42. PubMed ID: 26743104
[TBL] [Abstract] [Full Text] [Related]
5. High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma.
Alvino E; Passarelli F; Cannavò E; Fortes C; Mastroeni S; Caporali S; Jiricny J; Cappellini GC; Scoppola A; Marchetti P; Modesti A; D'Atri S
Am J Clin Pathol; 2014 Jul; 142(1):121-32. PubMed ID: 24926095
[TBL] [Abstract] [Full Text] [Related]
6. [Effectiveness of DNA repair and expression of MLH1, msh2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB; Lichinitser MR
Vopr Onkol; 2011; 57(2):165-72. PubMed ID: 21809660
[TBL] [Abstract] [Full Text] [Related]
7. Exonic deletions of mismatch repair genes MLH1 and msh2 correlate with prognosis and protein expression levels in malignant melanomas.
Korabiowska M; Brinck U; Stachura J; Jawien J; Hasse FM; Cordon-Cardos C; Fischer G
Anticancer Res; 2006; 26(2A):1231-5. PubMed ID: 16619529
[TBL] [Abstract] [Full Text] [Related]
8. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and msh2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract] [Full Text] [Related]
